Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Vandetanib/bicalutamide combination trial does not meet primary endpoint

Oct. 20, 2011

BeiGene in-licenses two clinical-stage oncology candidates

Oct. 20, 2011

New carbazole-linked hybrid antitumor agents prepared

Oct. 20, 2011

Lilly begins phase II study of LY-2510924 in SCLC

Oct. 20, 2011

CSIR presents new antitumor agents

Oct. 19, 2011

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Oct. 19, 2011

Orantinib advances through studies in NSCLC and breast cancer

Oct. 19, 2011

Halozyme discloses clinical results on new Herceptin formulation

Oct. 19, 2011

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Oct. 19, 2011

Interim first-in-human data released on two c-Met inhibitors

Oct. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...